HRP20040534A2 - Hiv integrase inhibitors - Google Patents
Hiv integrase inhibitorsInfo
- Publication number
- HRP20040534A2 HRP20040534A2 HR20040534A HRP20040534A HRP20040534A2 HR P20040534 A2 HRP20040534 A2 HR P20040534A2 HR 20040534 A HR20040534 A HR 20040534A HR P20040534 A HRP20040534 A HR P20040534A HR P20040534 A2 HRP20040534 A2 HR P20040534A2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- compound
- image
- aryl
- benzyl
- Prior art date
Links
- 229940099797 HIV integrase inhibitor Drugs 0.000 title 1
- 239000003084 hiv integrase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 302
- 239000000203 mixture Substances 0.000 claims description 76
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 66
- 150000003839 salts Chemical class 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 34
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 29
- -1 -C3-C6 Chemical group 0.000 claims description 22
- 239000012453 solvate Substances 0.000 claims description 22
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 20
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 108010002459 HIV Integrase Proteins 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- UBJXQYGGGBFPFU-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[(4-fluoro-3-methylphenyl)methyl]-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(F)C(C)=C1 UBJXQYGGGBFPFU-UHFFFAOYSA-N 0.000 claims description 3
- YDEQMOHWDHVKTH-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-ethoxy-n-[(4-fluorophenyl)methyl]acetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OCC)CC1=CC=C(F)C=C1 YDEQMOHWDHVKTH-UHFFFAOYSA-N 0.000 claims description 3
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- QADSZEUUAQILGY-UHFFFAOYSA-N n-[(3-cyano-4-fluorophenyl)methyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(F)C(C#N)=C1 QADSZEUUAQILGY-UHFFFAOYSA-N 0.000 claims description 3
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims description 3
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 3
- GACIOSIZKMLELV-POHAHGRESA-N (z)-4-[(4-fluorophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(/O)=C/C(=O)N(OC)CC1=CC=C(F)C=C1 GACIOSIZKMLELV-POHAHGRESA-N 0.000 claims description 2
- JLUPGSPHOGFEOB-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[(4-fluorophenyl)methyl]-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(F)C=C1 JLUPGSPHOGFEOB-UHFFFAOYSA-N 0.000 claims description 2
- BDMFEPGKMLIYNY-UHFFFAOYSA-N 4-[(3,4-difluorophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=C(F)C(F)=C1 BDMFEPGKMLIYNY-UHFFFAOYSA-N 0.000 claims description 2
- SVIXFYLTJBBOMO-UHFFFAOYSA-N 4-[(3-bromo-4-fluorophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=C(F)C(Br)=C1 SVIXFYLTJBBOMO-UHFFFAOYSA-N 0.000 claims description 2
- FQXBUZHPTOIFPH-UHFFFAOYSA-N 4-[(3-cyano-4-fluorophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=C(F)C(C#N)=C1 FQXBUZHPTOIFPH-UHFFFAOYSA-N 0.000 claims description 2
- RRJDARGXOYTXNN-UHFFFAOYSA-N 4-[(4-fluoro-3-methylphenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=C(F)C(C)=C1 RRJDARGXOYTXNN-UHFFFAOYSA-N 0.000 claims description 2
- VVTORXJRSZVVLL-UHFFFAOYSA-N 4-[ethoxy-[(4-fluorophenyl)methyl]amino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OCC)CC1=CC=C(F)C=C1 VVTORXJRSZVVLL-UHFFFAOYSA-N 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 239000002835 hiv fusion inhibitor Substances 0.000 claims description 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- YOYZQYPQBXGYGP-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(F)C(F)=C1 YOYZQYPQBXGYGP-UHFFFAOYSA-N 0.000 claims description 2
- VUPLYDPQETXFOM-UHFFFAOYSA-N n-[(3-bromo-4-fluorophenyl)methyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(F)C(Br)=C1 VUPLYDPQETXFOM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 219
- 238000005160 1H NMR spectroscopy Methods 0.000 description 140
- 238000002360 preparation method Methods 0.000 description 123
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 98
- 125000003118 aryl group Chemical group 0.000 description 82
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 71
- 238000006243 chemical reaction Methods 0.000 description 69
- 239000003921 oil Substances 0.000 description 67
- 235000019198 oils Nutrition 0.000 description 67
- 239000007787 solid Substances 0.000 description 65
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 58
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 51
- 239000013078 crystal Substances 0.000 description 48
- 239000000243 solution Substances 0.000 description 46
- 239000000463 material Substances 0.000 description 42
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 38
- 239000002904 solvent Substances 0.000 description 37
- 150000001408 amides Chemical class 0.000 description 36
- TZHYVEYXMXLHKU-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetyl chloride Chemical compound CC1(C)OC(=O)C(=CC(Cl)=O)O1 TZHYVEYXMXLHKU-UHFFFAOYSA-N 0.000 description 34
- 229910001868 water Inorganic materials 0.000 description 34
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 33
- 229940125904 compound 1 Drugs 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 32
- 239000000741 silica gel Substances 0.000 description 31
- 229910002027 silica gel Inorganic materials 0.000 description 31
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 30
- 230000009467 reduction Effects 0.000 description 30
- 238000004587 chromatography analysis Methods 0.000 description 29
- 238000007127 saponification reaction Methods 0.000 description 29
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 29
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 25
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 25
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 24
- 235000019439 ethyl acetate Nutrition 0.000 description 24
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 24
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 23
- 229940093499 ethyl acetate Drugs 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 22
- 238000010828 elution Methods 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 229940002612 prodrug Drugs 0.000 description 19
- 239000000651 prodrug Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- 238000001704 evaporation Methods 0.000 description 16
- 230000008020 evaporation Effects 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- UHOVQNZJYSORNB-MZWXYZOWSA-N benzene-d6 Chemical compound [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1[2H] UHOVQNZJYSORNB-MZWXYZOWSA-N 0.000 description 14
- 241000725303 Human immunodeficiency virus Species 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 238000004821 distillation Methods 0.000 description 12
- 150000002085 enols Chemical group 0.000 description 12
- 208000030507 AIDS Diseases 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 239000000543 intermediate Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 125000000468 ketone group Chemical group 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- GOUHYARYYWKXHS-UHFFFAOYSA-N 4-formylbenzoic acid Chemical compound OC(=O)C1=CC=C(C=O)C=C1 GOUHYARYYWKXHS-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 108010061833 Integrases Proteins 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- YVPQVDVWOGWULH-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetic acid Chemical compound CC1(C)OC(=O)C(=CC(O)=O)O1 YVPQVDVWOGWULH-UHFFFAOYSA-N 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- IDQOCLIWDMZKBZ-BYPYZUCNSA-N 2-[(4s)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl]acetic acid Chemical compound CC1(C)O[C@@H](CC(O)=O)C(=O)O1 IDQOCLIWDMZKBZ-BYPYZUCNSA-N 0.000 description 4
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 150000002443 hydroxylamines Chemical class 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 150000002923 oximes Chemical class 0.000 description 4
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- SSKPTOYHAVNPQQ-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-methoxymethanimine Chemical compound CON=CC1=CC=C(F)C=C1 SSKPTOYHAVNPQQ-UHFFFAOYSA-N 0.000 description 3
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 3
- ZWUSBSHBFFPRNE-UHFFFAOYSA-N 3,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1Cl ZWUSBSHBFFPRNE-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- UMAPZJNDUWZTLG-MNDPQUGUSA-N [tert-butyl(diphenyl)silyl] (2z)-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetate Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OC(=O)\C=C1/OC(C)(C)OC1=O UMAPZJNDUWZTLG-MNDPQUGUSA-N 0.000 description 3
- 239000012346 acetyl chloride Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940124524 integrase inhibitor Drugs 0.000 description 3
- 239000002850 integrase inhibitor Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- DKGPHRYZMVRUOP-UHFFFAOYSA-N 1-(2,4-difluorophenyl)-n-methoxymethanimine Chemical compound CON=CC1=CC=C(F)C=C1F DKGPHRYZMVRUOP-UHFFFAOYSA-N 0.000 description 2
- USHGJMRUFDWSID-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)-n-methoxymethanamine Chemical compound CONCC1=CC=C(F)C=C1Cl USHGJMRUFDWSID-UHFFFAOYSA-N 0.000 description 2
- JIYZMWRBGSCLKC-UHFFFAOYSA-N 1-(2-chloro-4-fluorophenyl)-n-methoxymethanimine Chemical compound CON=CC1=CC=C(F)C=C1Cl JIYZMWRBGSCLKC-UHFFFAOYSA-N 0.000 description 2
- UTPRVPDUWHTABB-UHFFFAOYSA-N 1-(2-fluorophenyl)-n-methoxymethanamine Chemical compound CONCC1=CC=CC=C1F UTPRVPDUWHTABB-UHFFFAOYSA-N 0.000 description 2
- DZKAFXCIWQMWJV-UHFFFAOYSA-N 1-(2-fluorophenyl)-n-methoxymethanimine Chemical compound CON=CC1=CC=CC=C1F DZKAFXCIWQMWJV-UHFFFAOYSA-N 0.000 description 2
- NXNSTEDUBIFINQ-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-n-phenylmethoxymethanamine Chemical compound C1=C(Cl)C(Cl)=CC=C1CNOCC1=CC=CC=C1 NXNSTEDUBIFINQ-UHFFFAOYSA-N 0.000 description 2
- CYULYERRYLYCNT-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-n-phenylmethoxymethanimine Chemical compound C1=C(Cl)C(Cl)=CC=C1C=NOCC1=CC=CC=C1 CYULYERRYLYCNT-UHFFFAOYSA-N 0.000 description 2
- HIRQXZFWJDGDSR-UHFFFAOYSA-N 1-(3,4-difluorophenyl)-n-methoxymethanimine Chemical compound CON=CC1=CC=C(F)C(F)=C1 HIRQXZFWJDGDSR-UHFFFAOYSA-N 0.000 description 2
- IBCOTPBEANUYDC-UHFFFAOYSA-N 1-(3-bromo-4-fluorophenyl)-n-methoxymethanimine Chemical compound CON=CC1=CC=C(F)C(Br)=C1 IBCOTPBEANUYDC-UHFFFAOYSA-N 0.000 description 2
- JDDQJOIYAKIFRZ-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)-n-methoxymethanamine Chemical compound CONCC1=CC=C(F)C(Cl)=C1 JDDQJOIYAKIFRZ-UHFFFAOYSA-N 0.000 description 2
- MAOQFOAITNCGLS-UHFFFAOYSA-N 1-(3-fluoro-4-methylphenyl)-n-methoxymethanamine Chemical compound CONCC1=CC=C(C)C(F)=C1 MAOQFOAITNCGLS-UHFFFAOYSA-N 0.000 description 2
- DZJRYUUARYQHOC-UHFFFAOYSA-N 1-(3-fluoro-4-methylphenyl)-n-methoxymethanimine Chemical compound CON=CC1=CC=C(C)C(F)=C1 DZJRYUUARYQHOC-UHFFFAOYSA-N 0.000 description 2
- UZIVOFAFIGZNQE-UHFFFAOYSA-N 1-(3-fluorophenyl)-n-methoxymethanamine Chemical compound CONCC1=CC=CC(F)=C1 UZIVOFAFIGZNQE-UHFFFAOYSA-N 0.000 description 2
- CLDCNXSLULYBOZ-UHFFFAOYSA-N 1-(3-fluorophenyl)-n-methoxymethanimine Chemical compound CON=CC1=CC=CC(F)=C1 CLDCNXSLULYBOZ-UHFFFAOYSA-N 0.000 description 2
- WIVNOFPTDUVVBU-UHFFFAOYSA-N 1-(4-fluoro-3-methylphenyl)-n-methoxymethanamine Chemical compound CONCC1=CC=C(F)C(C)=C1 WIVNOFPTDUVVBU-UHFFFAOYSA-N 0.000 description 2
- BWTUGSXEXLZUSO-UHFFFAOYSA-N 1-(4-fluoro-3-methylphenyl)-n-methoxymethanimine Chemical compound CON=CC1=CC=C(F)C(C)=C1 BWTUGSXEXLZUSO-UHFFFAOYSA-N 0.000 description 2
- MKHHCBQVBDVLML-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-(2-methylpropoxy)methanamine Chemical compound CC(C)CONCC1=CC=C(F)C=C1 MKHHCBQVBDVLML-UHFFFAOYSA-N 0.000 description 2
- BLYQYTCWKHXTOO-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-(2-methylpropoxy)methanimine Chemical compound CC(C)CON=CC1=CC=C(F)C=C1 BLYQYTCWKHXTOO-UHFFFAOYSA-N 0.000 description 2
- RALQFAVJNYWIGJ-UHFFFAOYSA-N 1-(4-fluorophenyl)-n-methoxymethanamine Chemical compound CONCC1=CC=C(F)C=C1 RALQFAVJNYWIGJ-UHFFFAOYSA-N 0.000 description 2
- AHDYSTTZURBUQY-UHFFFAOYSA-N 1-[4-fluoro-2-(trifluoromethyl)phenyl]-n-methoxymethanamine Chemical compound CONCC1=CC=C(F)C=C1C(F)(F)F AHDYSTTZURBUQY-UHFFFAOYSA-N 0.000 description 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- AUTVUKNDJKKJLM-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[(3-fluoro-4-methylphenyl)methyl]-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(C)C(F)=C1 AUTVUKNDJKKJLM-UHFFFAOYSA-N 0.000 description 2
- LYJCDLSGQLNMQG-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[(4-fluorophenyl)methyl]-n-(2-methylpropoxy)acetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OCC(C)C)CC1=CC=C(F)C=C1 LYJCDLSGQLNMQG-UHFFFAOYSA-N 0.000 description 2
- QUFZYOCVXLYENT-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[2-(4-fluorophenyl)ethyl]-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CCC1=CC=C(F)C=C1 QUFZYOCVXLYENT-UHFFFAOYSA-N 0.000 description 2
- AQPNXEGSTCRLJI-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxy-n-[(2-methylphenyl)methyl]acetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=CC=C1C AQPNXEGSTCRLJI-UHFFFAOYSA-N 0.000 description 2
- BTJAWGBSLKBEQH-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]acetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(C(F)(F)F)C=C1 BTJAWGBSLKBEQH-UHFFFAOYSA-N 0.000 description 2
- HJWFRLPXVDBXHA-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-methoxyethanimine Chemical compound CON=CCC1=CC=C(F)C=C1 HJWFRLPXVDBXHA-UHFFFAOYSA-N 0.000 description 2
- LJHGQGCOSJUZSQ-UHFFFAOYSA-N 2-[(4-fluorophenyl)methylamino]oxy-n,n-dimethylethanamine Chemical compound CN(C)CCONCC1=CC=C(F)C=C1 LJHGQGCOSJUZSQ-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- RAPMRWVLYAFPQJ-UHFFFAOYSA-N 2-[[2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetyl]-[(4-fluorophenyl)methyl]amino]oxyacetic acid Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OCC(O)=O)CC1=CC=C(F)C=C1 RAPMRWVLYAFPQJ-UHFFFAOYSA-N 0.000 description 2
- GHDUNBWEXKJTHZ-UHFFFAOYSA-N 2-fluoro-5-(methoxyiminomethyl)benzonitrile Chemical compound CON=CC1=CC=C(F)C(C#N)=C1 GHDUNBWEXKJTHZ-UHFFFAOYSA-N 0.000 description 2
- NIGFABCQVISRTE-UHFFFAOYSA-N 2-fluoro-5-[(methoxyamino)methyl]benzonitrile Chemical compound CONCC1=CC=C(F)C(C#N)=C1 NIGFABCQVISRTE-UHFFFAOYSA-N 0.000 description 2
- ZDZGDEUBKWQUHK-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-n-methoxypropan-1-imine Chemical compound CON=CCCC1=CC=C(Cl)C(Cl)=C1 ZDZGDEUBKWQUHK-UHFFFAOYSA-N 0.000 description 2
- KEKAVYSPLYIQBK-UHFFFAOYSA-N 3-(4-fluorophenyl)-n-methoxypropan-1-imine Chemical compound CON=CCCC1=CC=C(F)C=C1 KEKAVYSPLYIQBK-UHFFFAOYSA-N 0.000 description 2
- QVGXUVXKJGOXGN-UHFFFAOYSA-N 4-(methoxyiminomethyl)benzonitrile Chemical compound CON=CC1=CC=C(C#N)C=C1 QVGXUVXKJGOXGN-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QXQUMNAPQVVZPE-UHFFFAOYSA-N 4-[(methoxyamino)methyl]benzonitrile Chemical compound CONCC1=CC=C(C#N)C=C1 QXQUMNAPQVVZPE-UHFFFAOYSA-N 0.000 description 2
- UIADWSXPNFQQCZ-UHFFFAOYSA-N 4-[4-(3,4-dichlorophenyl)-5-phenyl-1,3-oxazol-2-yl]butanoic acid Chemical compound ClC=1C=C(C=CC=1Cl)C=1N=C(OC=1C1=CC=CC=C1)CCCC(=O)O UIADWSXPNFQQCZ-UHFFFAOYSA-N 0.000 description 2
- FQODHPQGPRNUEU-UHFFFAOYSA-N 4-[[[2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetyl]-methoxyamino]methyl]benzoic acid Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(C(O)=O)C=C1 FQODHPQGPRNUEU-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 2
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- CLTCOVNCWYABTF-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] 2-(4-bromo-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)acetate Chemical compound CC(C)(C)[Si](C)(C)OC(=O)CC1(Br)OC(C)(C)OC1=O CLTCOVNCWYABTF-UHFFFAOYSA-N 0.000 description 2
- QGGVVHRHARMWGJ-UHFFFAOYSA-N [tert-butyl(diphenyl)silyl] 2-(4-bromo-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)acetate Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)OC(=O)CC1(Br)OC(C)(C)OC1=O QGGVVHRHARMWGJ-UHFFFAOYSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 239000012039 electrophile Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- BFRLTYGVUGLUNT-UHFFFAOYSA-N methyl 4-(methoxyiminomethyl)benzoate Chemical compound CON=CC1=CC=C(C(=O)OC)C=C1 BFRLTYGVUGLUNT-UHFFFAOYSA-N 0.000 description 2
- HCVOOYSVPKIRCI-UHFFFAOYSA-N methyl 4-[(methoxyamino)methyl]benzoate Chemical compound CONCC1=CC=C(C(=O)OC)C=C1 HCVOOYSVPKIRCI-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- PUCZZVXAMBDFFE-UHFFFAOYSA-N n-(2-chloroethoxy)-1-(4-fluorophenyl)methanamine Chemical compound FC1=CC=C(CNOCCCl)C=C1 PUCZZVXAMBDFFE-UHFFFAOYSA-N 0.000 description 2
- AIXJJHLKLRCOLC-UHFFFAOYSA-N n-(2-chloroethoxy)-1-(4-fluorophenyl)methanimine Chemical compound FC1=CC=C(C=NOCCCl)C=C1 AIXJJHLKLRCOLC-UHFFFAOYSA-N 0.000 description 2
- SOSIUXKHWSNPAB-UHFFFAOYSA-N n-[(2,4-difluorophenyl)methyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(F)C=C1F SOSIUXKHWSNPAB-UHFFFAOYSA-N 0.000 description 2
- WNMBJXCFMOCPGN-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(Cl)C(Cl)=C1 WNMBJXCFMOCPGN-UHFFFAOYSA-N 0.000 description 2
- PDHHMENDJBHSNQ-UHFFFAOYSA-N n-[(3,4-dichlorophenyl)methyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-phenylmethoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OCC=1C=CC=CC=1)CC1=CC=C(Cl)C(Cl)=C1 PDHHMENDJBHSNQ-UHFFFAOYSA-N 0.000 description 2
- MQBHIWADAIVNNH-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(Cl)C=C1 MQBHIWADAIVNNH-UHFFFAOYSA-N 0.000 description 2
- VJNYDHXANJWDAM-UHFFFAOYSA-N n-[4-(methoxyiminomethyl)phenyl]acetamide Chemical compound CON=CC1=CC=C(NC(C)=O)C=C1 VJNYDHXANJWDAM-UHFFFAOYSA-N 0.000 description 2
- KXKNGSIEXBDYDS-UHFFFAOYSA-N n-benzyl-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-phenylmethoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OCC=1C=CC=CC=1)CC1=CC=CC=C1 KXKNGSIEXBDYDS-UHFFFAOYSA-N 0.000 description 2
- LUDAZDYIHBLDSO-UHFFFAOYSA-N n-ethoxy-1-(4-fluorophenyl)methanamine Chemical compound CCONCC1=CC=C(F)C=C1 LUDAZDYIHBLDSO-UHFFFAOYSA-N 0.000 description 2
- VILHMJQDENLMDM-UHFFFAOYSA-N n-ethoxy-1-(4-fluorophenyl)methanimine Chemical compound CCON=CC1=CC=C(F)C=C1 VILHMJQDENLMDM-UHFFFAOYSA-N 0.000 description 2
- VLJGYFQPRGNGOV-UHFFFAOYSA-N n-methoxy-1-(2-methylphenyl)methanamine Chemical compound CONCC1=CC=CC=C1C VLJGYFQPRGNGOV-UHFFFAOYSA-N 0.000 description 2
- QNQLSNUROIGIRL-UHFFFAOYSA-N n-methoxy-1-(2-methylphenyl)methanimine Chemical compound CON=CC1=CC=CC=C1C QNQLSNUROIGIRL-UHFFFAOYSA-N 0.000 description 2
- JCBUKLFOJIWOER-UHFFFAOYSA-N n-methoxy-1-(2-propan-2-yloxyphenyl)methanimine Chemical compound CON=CC1=CC=CC=C1OC(C)C JCBUKLFOJIWOER-UHFFFAOYSA-N 0.000 description 2
- FRLGNZPYLCIAQC-UHFFFAOYSA-N n-methoxy-1-(4-methoxyphenyl)methanimine Chemical compound CON=CC1=CC=C(OC)C=C1 FRLGNZPYLCIAQC-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- BTFQKIATRPGRBS-UHFFFAOYSA-N o-tolualdehyde Chemical compound CC1=CC=CC=C1C=O BTFQKIATRPGRBS-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 229960002317 succinimide Drugs 0.000 description 2
- 229910052717 sulfur Chemical group 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XXUZVVSDTZVISD-UHFFFAOYSA-N tert-butyl 2-[(3,4-dichlorophenyl)methylamino]oxyacetate Chemical compound CC(C)(C)OC(=O)CONCC1=CC=C(Cl)C(Cl)=C1 XXUZVVSDTZVISD-UHFFFAOYSA-N 0.000 description 2
- OIUTXXWRKMIGMF-UHFFFAOYSA-N tert-butyl 2-[(3,4-dichlorophenyl)methylideneamino]oxyacetate Chemical compound CC(C)(C)OC(=O)CON=CC1=CC=C(Cl)C(Cl)=C1 OIUTXXWRKMIGMF-UHFFFAOYSA-N 0.000 description 2
- IITAFWUULUCYRH-UHFFFAOYSA-N tert-butyl 2-[(4-fluorophenyl)methylamino]oxyacetate Chemical compound CC(C)(C)OC(=O)CONCC1=CC=C(F)C=C1 IITAFWUULUCYRH-UHFFFAOYSA-N 0.000 description 2
- KJPCPNYUBIYDNS-UHFFFAOYSA-N tert-butyl 2-[(4-fluorophenyl)methylideneamino]oxyacetate Chemical compound CC(C)(C)OC(=O)CON=CC1=CC=C(F)C=C1 KJPCPNYUBIYDNS-UHFFFAOYSA-N 0.000 description 2
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 2
- SDHRVMNTGUAJJE-UHFFFAOYSA-N tert-butyl 4-(methoxyiminomethyl)benzoate Chemical compound CON=CC1=CC=C(C(=O)OC(C)(C)C)C=C1 SDHRVMNTGUAJJE-UHFFFAOYSA-N 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- XTYSXGHMTNTKFH-BDEHJDMKSA-N (2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate Chemical compound O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 XTYSXGHMTNTKFH-BDEHJDMKSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ROBIUDOANJUDHD-ONNFQVAWSA-N (ne)-n-[(3,4-dichlorophenyl)methylidene]hydroxylamine Chemical compound O\N=C\C1=CC=C(Cl)C(Cl)=C1 ROBIUDOANJUDHD-ONNFQVAWSA-N 0.000 description 1
- MDXFLDHCQHBQAT-UHFFFAOYSA-N 1,1-dichloroethane;hexane Chemical compound CC(Cl)Cl.CCCCCC MDXFLDHCQHBQAT-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- RJHSCNDWZIYZRH-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-n-methoxymethanamine Chemical compound CONCC1=CC=C(Cl)C(Cl)=C1 RJHSCNDWZIYZRH-UHFFFAOYSA-N 0.000 description 1
- NAPWAZLPWIRSFY-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-methoxymethanamine Chemical compound CONCC1=CC=C(Cl)C=C1 NAPWAZLPWIRSFY-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- ATTIFERTNAWNMS-UHFFFAOYSA-N 1-[4-fluoro-2-(trifluoromethyl)phenyl]-n-methoxymethanimine Chemical compound CON=CC1=CC=C(F)C=C1C(F)(F)F ATTIFERTNAWNMS-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- WUUIYHZKEXDJKH-UHFFFAOYSA-N 1-phenyl-n-phenylmethoxymethanamine Chemical compound C=1C=CC=CC=1CNOCC1=CC=CC=C1 WUUIYHZKEXDJKH-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- WCGPCBACLBHDCI-UHFFFAOYSA-N 2,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(F)=C1 WCGPCBACLBHDCI-UHFFFAOYSA-N 0.000 description 1
- HRJBKPAXGMUMAE-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[(2-fluorophenyl)methyl]-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=CC=C1F HRJBKPAXGMUMAE-UHFFFAOYSA-N 0.000 description 1
- DWFCPSKTNKPJMH-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[(3-fluorophenyl)methyl]-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=CC(F)=C1 DWFCPSKTNKPJMH-UHFFFAOYSA-N 0.000 description 1
- BRZSSFRHLUCZMB-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[3-(4-fluorophenyl)propyl]-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CCCC1=CC=C(F)C=C1 BRZSSFRHLUCZMB-UHFFFAOYSA-N 0.000 description 1
- YDWRVJPYQFDQNW-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(F)C=C1C(F)(F)F YDWRVJPYQFDQNW-UHFFFAOYSA-N 0.000 description 1
- UJYSPWWLNRFOMM-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxy-n-[(2-propan-2-yloxyphenyl)methyl]acetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=CC=C1OC(C)C UJYSPWWLNRFOMM-UHFFFAOYSA-N 0.000 description 1
- DCKFDDQLDSYLJF-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxy-n-[(4-methoxyphenyl)methyl]acetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(OC)C=C1 DCKFDDQLDSYLJF-UHFFFAOYSA-N 0.000 description 1
- IOPDBFMRRVJEHN-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxy-n-[(4-methylphenyl)methyl]acetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(C)C=C1 IOPDBFMRRVJEHN-UHFFFAOYSA-N 0.000 description 1
- LYICFXGHVZHFJR-UHFFFAOYSA-N 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound CONC(=O)C=C1OC(C)(C)OC1=O LYICFXGHVZHFJR-UHFFFAOYSA-N 0.000 description 1
- YBFGCGKANVNTMW-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-methoxyethanamine Chemical compound CONCCC1=CC=C(F)C=C1 YBFGCGKANVNTMW-UHFFFAOYSA-N 0.000 description 1
- KCXZRESSSSYYCW-UHFFFAOYSA-N 2-(4-fluorophenyl)acetaldehyde Chemical compound FC1=CC=C(CC=O)C=C1 KCXZRESSSSYYCW-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LIDNAXWPTAHRHP-UHFFFAOYSA-N 2-[[2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetyl]-[(4-fluorophenyl)methyl]amino]oxy-n,n-dimethylacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OCC(=O)N(C)C)CC1=CC=C(F)C=C1 LIDNAXWPTAHRHP-UHFFFAOYSA-N 0.000 description 1
- MKRUVMYCYCNKIX-UHFFFAOYSA-N 2-[[2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetyl]-[(4-fluorophenyl)methyl]amino]oxyacetyl chloride Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OCC(Cl)=O)CC1=CC=C(F)C=C1 MKRUVMYCYCNKIX-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- KMQWNQKESAHDKD-UHFFFAOYSA-N 2-chloro-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(Cl)=C1 KMQWNQKESAHDKD-UHFFFAOYSA-N 0.000 description 1
- MOFRJTLODZILCR-UHFFFAOYSA-N 2-fluoro-5-formylbenzonitrile Chemical compound FC1=CC=C(C=O)C=C1C#N MOFRJTLODZILCR-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- NKSLFPOAYPBOQX-UHFFFAOYSA-N 2-hydroxy-4-[methoxy-[(2-methylphenyl)methyl]amino]-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=CC=C1C NKSLFPOAYPBOQX-UHFFFAOYSA-N 0.000 description 1
- KBZPWMOHSOEQRR-UHFFFAOYSA-N 2-hydroxy-4-[methoxy-[(2-propan-2-yloxyphenyl)methyl]amino]-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=CC=C1OC(C)C KBZPWMOHSOEQRR-UHFFFAOYSA-N 0.000 description 1
- MGSNVOBGXVQLFK-UHFFFAOYSA-N 2-hydroxy-4-[methoxy-[(4-methoxycarbonylphenyl)methyl]amino]-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=C(C(=O)OC)C=C1 MGSNVOBGXVQLFK-UHFFFAOYSA-N 0.000 description 1
- HAGKSVQUCRYPEH-UHFFFAOYSA-N 2-hydroxy-4-[methoxy-[[4-(trifluoromethyl)phenyl]methyl]amino]-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=C(C(F)(F)F)C=C1 HAGKSVQUCRYPEH-UHFFFAOYSA-N 0.000 description 1
- FEWFXBUNENSNBQ-UHFFFAOYSA-N 2-hydroxyacrylic acid Chemical compound OC(=C)C(O)=O FEWFXBUNENSNBQ-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- ZZJVNPRHHLLANO-UHFFFAOYSA-N 2-propan-2-yloxybenzaldehyde Chemical compound CC(C)OC1=CC=CC=C1C=O ZZJVNPRHHLLANO-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- JPHKMYXKNKLNDF-UHFFFAOYSA-N 3,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1F JPHKMYXKNKLNDF-UHFFFAOYSA-N 0.000 description 1
- UBUQWRXGPBSBSK-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)propanal Chemical compound ClC1=CC=C(CCC=O)C=C1Cl UBUQWRXGPBSBSK-UHFFFAOYSA-N 0.000 description 1
- DURVHEUBLYIRKD-UHFFFAOYSA-N 3-(4-fluorophenyl)-n-methoxypropan-1-amine Chemical compound CONCCCC1=CC=C(F)C=C1 DURVHEUBLYIRKD-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- FAHZIKXYYRGSHF-UHFFFAOYSA-N 3-bromo-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1Br FAHZIKXYYRGSHF-UHFFFAOYSA-N 0.000 description 1
- GVORVQPNNSASDM-UHFFFAOYSA-N 3-chloro-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1Cl GVORVQPNNSASDM-UHFFFAOYSA-N 0.000 description 1
- UFPBMVRONDLOGK-UHFFFAOYSA-N 3-fluoro-4-methylbenzaldehyde Chemical compound CC1=CC=C(C=O)C=C1F UFPBMVRONDLOGK-UHFFFAOYSA-N 0.000 description 1
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- IYTJRMRETHPZAC-UHFFFAOYSA-N 4,4-dibenzylpiperidine Chemical compound C1CNCCC1(CC=1C=CC=CC=1)CC1=CC=CC=C1 IYTJRMRETHPZAC-UHFFFAOYSA-N 0.000 description 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
- SKLUWKYNZNXSLX-UHFFFAOYSA-N 4-Acetamidobenzaldehyde Chemical compound CC(=O)NC1=CC=C(C=O)C=C1 SKLUWKYNZNXSLX-UHFFFAOYSA-N 0.000 description 1
- GDBYIFQIYKUTSC-UHFFFAOYSA-N 4-[(2,4-difluorophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=C(F)C=C1F GDBYIFQIYKUTSC-UHFFFAOYSA-N 0.000 description 1
- IZMMYOMNDAVUEO-UHFFFAOYSA-N 4-[(2-chloro-4-fluorophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=C(F)C=C1Cl IZMMYOMNDAVUEO-UHFFFAOYSA-N 0.000 description 1
- RRGXTXPUUMADNB-UHFFFAOYSA-N 4-[(2-fluorophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=CC=C1F RRGXTXPUUMADNB-UHFFFAOYSA-N 0.000 description 1
- ZZQIXUMNHKJWRH-UHFFFAOYSA-N 4-[(3,4-dichlorophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=C(Cl)C(Cl)=C1 ZZQIXUMNHKJWRH-UHFFFAOYSA-N 0.000 description 1
- LTVSFWLJOMRZER-UHFFFAOYSA-N 4-[(3,4-dichlorophenyl)methyl-phenylmethoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound C=1C=CC=CC=1CON(C(=O)C=C(O)C(=O)O)CC1=CC=C(Cl)C(Cl)=C1 LTVSFWLJOMRZER-UHFFFAOYSA-N 0.000 description 1
- FIUNTHTVULGJKT-UHFFFAOYSA-N 4-[(3-chloro-4-fluorophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=C(F)C(Cl)=C1 FIUNTHTVULGJKT-UHFFFAOYSA-N 0.000 description 1
- ZTFODMKZPOHBLB-UHFFFAOYSA-N 4-[(3-fluoro-4-methylphenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=C(C)C(F)=C1 ZTFODMKZPOHBLB-UHFFFAOYSA-N 0.000 description 1
- HBJFJOHBIIUUKO-UHFFFAOYSA-N 4-[(4-chlorophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=C(Cl)C=C1 HBJFJOHBIIUUKO-UHFFFAOYSA-N 0.000 description 1
- ARJGXGCIXQLKSH-UHFFFAOYSA-N 4-[(4-cyanophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=C(C#N)C=C1 ARJGXGCIXQLKSH-UHFFFAOYSA-N 0.000 description 1
- CGBZRIDHBXJWOX-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]amino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound CC(C)(C)OC(=O)CON(C(=O)C=C(O)C(O)=O)CC1=CC=C(F)C=C1 CGBZRIDHBXJWOX-UHFFFAOYSA-N 0.000 description 1
- OAAOPELPGMJZKM-UHFFFAOYSA-N 4-[(methoxyamino)methyl]benzoic acid Chemical compound CONCC1=CC=C(C(O)=O)C=C1 OAAOPELPGMJZKM-UHFFFAOYSA-N 0.000 description 1
- DOVHMFPODADMIU-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)ethyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CCC1=CC=C(F)C=C1 DOVHMFPODADMIU-UHFFFAOYSA-N 0.000 description 1
- YILVEFPZRFSVAE-UHFFFAOYSA-N 4-[[2-(dimethylamino)-2-oxoethoxy]-[(4-fluorophenyl)methyl]amino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound CN(C)C(=O)CON(C(=O)C=C(O)C(O)=O)CC1=CC=C(F)C=C1 YILVEFPZRFSVAE-UHFFFAOYSA-N 0.000 description 1
- OQTNEENOCHZUHF-UHFFFAOYSA-N 4-[benzyl(methoxy)amino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OC)CC1=CC=CC=C1 OQTNEENOCHZUHF-UHFFFAOYSA-N 0.000 description 1
- TZFHLNNBHAMFTF-UHFFFAOYSA-N 4-[benzyl(phenylmethoxy)amino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound C=1C=CC=CC=1CON(C(=O)C=C(O)C(=O)O)CC1=CC=CC=C1 TZFHLNNBHAMFTF-UHFFFAOYSA-N 0.000 description 1
- DTOMQVQTJZMBSR-UHFFFAOYSA-N 4-[carboxymethoxy-[(4-fluorophenyl)methyl]amino]-2-hydroxy-4-oxobut-2-enoic acid Chemical compound OC(=O)C(O)=CC(=O)N(OCC(=O)O)CC1=CC=C(F)C=C1 DTOMQVQTJZMBSR-UHFFFAOYSA-N 0.000 description 1
- WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 1
- NONOHEMDNFTKCZ-UHFFFAOYSA-N 4-fluoro-2-(trifluoromethyl)benzaldehyde Chemical compound FC1=CC=C(C=O)C(C(F)(F)F)=C1 NONOHEMDNFTKCZ-UHFFFAOYSA-N 0.000 description 1
- NRFKZFFVTGGEQF-UHFFFAOYSA-N 4-fluoro-3-methylbenzaldehyde Chemical compound CC1=CC(C=O)=CC=C1F NRFKZFFVTGGEQF-UHFFFAOYSA-N 0.000 description 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 238000003512 Claisen condensation reaction Methods 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 description 1
- ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- OGQYILZPBITSSN-UHFFFAOYSA-N NS(O)(=O)=O.OC(=O)C=CC(O)=O Chemical compound NS(O)(=O)=O.OC(=O)C=CC(O)=O OGQYILZPBITSSN-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- UZUBJZMQRZAEFN-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] 2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl)acetate Chemical compound CC(C)(C)[Si](C)(C)OC(=O)CC1OC(C)(C)OC1=O UZUBJZMQRZAEFN-UHFFFAOYSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- XTCGYRFLVLFRGW-UHFFFAOYSA-N acronycidine Chemical compound COC1=C2C=COC2=NC2=C(OC)C(OC)=CC(OC)=C21 XTCGYRFLVLFRGW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine mesylate Natural products CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 150000004862 dioxolanes Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- RBBOWEDMXHTEPA-UHFFFAOYSA-N hexane;toluene Chemical compound CCCCCC.CC1=CC=CC=C1 RBBOWEDMXHTEPA-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- FJJNBFZIXIXJBK-UHFFFAOYSA-N methyl 4-[[[2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetyl]-methoxyamino]methyl]benzoate Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(C(=O)OC)C=C1 FJJNBFZIXIXJBK-UHFFFAOYSA-N 0.000 description 1
- FEIOASZZURHTHB-UHFFFAOYSA-N methyl 4-formylbenzoate Chemical compound COC(=O)C1=CC=C(C=O)C=C1 FEIOASZZURHTHB-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- YGDXSNLXSAZGRW-UHFFFAOYSA-N n-[(2-chloro-4-fluorophenyl)methyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(F)C=C1Cl YGDXSNLXSAZGRW-UHFFFAOYSA-N 0.000 description 1
- FADRTDUQGASTDK-UHFFFAOYSA-N n-[(3-chloro-4-fluorophenyl)methyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(F)C(Cl)=C1 FADRTDUQGASTDK-UHFFFAOYSA-N 0.000 description 1
- CVNCSYJAPVSHQR-UHFFFAOYSA-N n-[(4-acetamidophenyl)methyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(NC(C)=O)C=C1 CVNCSYJAPVSHQR-UHFFFAOYSA-N 0.000 description 1
- DOAPOPWPJKBJNR-UHFFFAOYSA-N n-[(4-cyanophenyl)methyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(C#N)C=C1 DOAPOPWPJKBJNR-UHFFFAOYSA-N 0.000 description 1
- FSKSLWXDUJVTHE-UHFFFAOYSA-N n-[(4-fluorophenyl)methylidene]hydroxylamine Chemical compound ON=CC1=CC=C(F)C=C1 FSKSLWXDUJVTHE-UHFFFAOYSA-N 0.000 description 1
- PXSXPNLIKMFSAD-UHFFFAOYSA-N n-[2-(dimethylamino)ethoxy]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-[(4-fluorophenyl)methyl]acetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OCCN(C)C)CC1=CC=C(F)C=C1 PXSXPNLIKMFSAD-UHFFFAOYSA-N 0.000 description 1
- HEGLSZNRIWITES-UHFFFAOYSA-N n-[3-(3,4-dichlorophenyl)propyl]-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CCCC1=CC=C(Cl)C(Cl)=C1 HEGLSZNRIWITES-UHFFFAOYSA-N 0.000 description 1
- SJVBICCMBKDBGR-UHFFFAOYSA-N n-[4-[(methoxyamino)methyl]phenyl]acetamide Chemical compound CONCC1=CC=C(NC(C)=O)C=C1 SJVBICCMBKDBGR-UHFFFAOYSA-N 0.000 description 1
- HSVQNPIQSWNKSW-UHFFFAOYSA-N n-benzyl-2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)-n-methoxyacetamide Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=CC=C1 HSVQNPIQSWNKSW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- YBBMCHHXDYQGRU-UHFFFAOYSA-N n-methoxy-1-(2-propan-2-yloxyphenyl)methanamine Chemical compound CONCC1=CC=CC=C1OC(C)C YBBMCHHXDYQGRU-UHFFFAOYSA-N 0.000 description 1
- SHZLRNHMPUWSGH-UHFFFAOYSA-N n-methoxy-1-(4-methoxyphenyl)methanamine Chemical compound CONCC1=CC=C(OC)C=C1 SHZLRNHMPUWSGH-UHFFFAOYSA-N 0.000 description 1
- UCYSOTAMOJUSJH-UHFFFAOYSA-N n-methoxy-1-(4-methylphenyl)methanimine Chemical compound CON=CC1=CC=C(C)C=C1 UCYSOTAMOJUSJH-UHFFFAOYSA-N 0.000 description 1
- OGBMATVBOAYZBA-UHFFFAOYSA-N n-methoxy-1-[4-(trifluoromethyl)phenyl]methanamine Chemical compound CONCC1=CC=C(C(F)(F)F)C=C1 OGBMATVBOAYZBA-UHFFFAOYSA-N 0.000 description 1
- ZLAXDJDWMUZFPQ-UHFFFAOYSA-N n-methoxy-1-[4-(trifluoromethyl)phenyl]methanimine Chemical compound CON=CC1=CC=C(C(F)(F)F)C=C1 ZLAXDJDWMUZFPQ-UHFFFAOYSA-N 0.000 description 1
- QWLISCJHYITNQF-UHFFFAOYSA-N n-methoxy-1-phenylmethanamine Chemical compound CONCC1=CC=CC=C1 QWLISCJHYITNQF-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960000884 nelfinavir Drugs 0.000 description 1
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- WOXGREIMSJFDPG-UHFFFAOYSA-N o-(2-methylpropyl)hydroxylamine;hydrochloride Chemical compound Cl.CC(C)CON WOXGREIMSJFDPG-UHFFFAOYSA-N 0.000 description 1
- NUXCOKIYARRTDC-UHFFFAOYSA-N o-ethylhydroxylamine;hydron;chloride Chemical compound Cl.CCON NUXCOKIYARRTDC-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- SEVSMVUOKAMPDO-UHFFFAOYSA-N para-Acetoxybenzaldehyde Natural products CC(=O)OC1=CC=C(C=O)C=C1 SEVSMVUOKAMPDO-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- KBMCDHMMFSAPQO-UHFFFAOYSA-N tert-butyl 2-[[2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetyl]-[(4-fluorophenyl)methyl]amino]oxyacetate Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OCC(=O)OC(C)(C)C)CC1=CC=C(F)C=C1 KBMCDHMMFSAPQO-UHFFFAOYSA-N 0.000 description 1
- WTRSPCWVOHYGHT-UHFFFAOYSA-N tert-butyl 4-[(methoxyamino)methyl]benzoate Chemical compound CONCC1=CC=C(C(=O)OC(C)(C)C)C=C1 WTRSPCWVOHYGHT-UHFFFAOYSA-N 0.000 description 1
- MAAXDJXZWPPIBE-UHFFFAOYSA-N tert-butyl 4-[[[2-(2,2-dimethyl-5-oxo-1,3-dioxolan-4-ylidene)acetyl]-methoxyamino]methyl]benzoate Chemical compound O1C(C)(C)OC(=O)C1=CC(=O)N(OC)CC1=CC=C(C(=O)OC(C)(C)C)C=C1 MAAXDJXZWPPIBE-UHFFFAOYSA-N 0.000 description 1
- AGOSGCWATIJZHQ-UHFFFAOYSA-N tert-butyl [(2-methylpropan-2-yl)oxycarbonylamino] carbonate Chemical compound CC(C)(C)OC(=O)NOC(=O)OC(C)(C)C AGOSGCWATIJZHQ-UHFFFAOYSA-N 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
- C07C207/04—Compounds containing nitroso groups bound to a carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
- C07C239/08—Hydroxylamino compounds or their ethers or esters
- C07C239/20—Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/63—Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton
- C07C255/64—Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton with the nitrogen atoms further bound to oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33967401P | 2001-12-12 | 2001-12-12 | |
PCT/US2002/039092 WO2003049690A2 (en) | 2001-12-12 | 2002-12-06 | Hiv integrase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20040534A2 true HRP20040534A2 (en) | 2005-04-30 |
Family
ID=23330105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20040534A HRP20040534A2 (en) | 2001-12-12 | 2004-06-11 | Hiv integrase inhibitors |
Country Status (24)
Country | Link |
---|---|
US (1) | US6777440B2 (is) |
EP (1) | EP1467695A2 (is) |
JP (1) | JP2005515206A (is) |
KR (1) | KR20040065251A (is) |
CN (1) | CN1617849A (is) |
AR (1) | AR037770A1 (is) |
AU (1) | AU2002366604A1 (is) |
BR (1) | BR0214842A (is) |
CA (1) | CA2469592C (is) |
CO (1) | CO5590909A2 (is) |
HR (1) | HRP20040534A2 (is) |
HU (1) | HUP0402675A2 (is) |
IL (1) | IL162325A0 (is) |
IS (1) | IS7305A (is) |
MX (1) | MXPA04005623A (is) |
NO (1) | NO20042916L (is) |
NZ (1) | NZ533413A (is) |
PE (1) | PE20030763A1 (is) |
PL (1) | PL370664A1 (is) |
RU (1) | RU2284315C2 (is) |
TW (1) | TWI252757B (is) |
UY (1) | UY27577A1 (is) |
WO (1) | WO2003049690A2 (is) |
ZA (1) | ZA200404628B (is) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7094909B2 (en) | 2001-06-11 | 2006-08-22 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis |
US7169932B2 (en) | 2001-06-11 | 2007-01-30 | Pfizer Inc. | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis |
HN2002000136A (es) | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
PA8586801A1 (es) | 2002-10-31 | 2005-02-04 | Pfizer | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso |
CA2513141A1 (en) | 2003-01-27 | 2004-08-12 | Pfizer Inc. | Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use |
US6890942B2 (en) * | 2003-05-16 | 2005-05-10 | Bristol-Myers Squibb Company | Acyl sulfonamides as inhibitors of HIV integrase |
US7776863B2 (en) * | 2004-03-24 | 2010-08-17 | Bristol-Myers Squibb Company | Methods of treating HIV infection |
US20050215544A1 (en) * | 2004-03-24 | 2005-09-29 | Pin-Fang Lin | Methods of treating HIV infection |
MXPA06012342A (es) | 2004-04-26 | 2007-01-17 | Pfizer | Inhibidores de la enzima integrasa del virus de la inmunodeficiencia humana. |
WO2005103003A2 (en) | 2004-04-26 | 2005-11-03 | Pfizer Inc. | Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors |
US7507838B2 (en) * | 2004-09-01 | 2009-03-24 | Bristol-Myers Squibb Company | Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones |
US20060058286A1 (en) * | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
WO2007086584A1 (ja) * | 2006-01-30 | 2007-08-02 | Meiji Seika Kaisha, Ltd. | 新規FabKおよびFabI/K阻害剤 |
WO2008004100A2 (en) | 2006-07-05 | 2008-01-10 | Pfizer Products Inc. | Therapeutic compounds |
PT2364293E (pt) * | 2008-12-05 | 2013-04-26 | Syngenta Participations Ag | Novas pirazol-4-n-alcoxicarboxamidas como microbiocidas |
US20120316161A1 (en) | 2009-12-23 | 2012-12-13 | Katholieke Universiteit Leuven | Novel antiviral compounds |
US8283366B2 (en) | 2010-01-22 | 2012-10-09 | Ambrilia Biopharma, Inc. | Derivatives of pyridoxine for inhibiting HIV integrase |
CA2817896A1 (en) | 2010-11-15 | 2012-05-24 | Viiv Healthcare Uk Limited | Inhibitors of hiv replication |
EP2640705A2 (en) | 2010-11-15 | 2013-09-25 | Katholieke Universiteit Leuven | Novel antiviral compounds |
CN104245660A (zh) * | 2012-04-26 | 2014-12-24 | 拜尔农科股份公司 | 制备n-(5-氯-2-异丙基苄基)-环丙胺的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR029304A1 (es) * | 1998-06-26 | 2003-06-25 | Daiichi Seiyaku Co | DERIVADOS DE PROPIONILO SUSTITUIDOS, PRODUCTO FARMACEUTICO, USO PARA LA FABRICACION DE UNA COMPOSICION FARMACEUTICA PARA LA PREVENCION Y/O TRATAMIENTO DE HIPERCOLESTEROLEMIA, HIPERLIPEMIA O ARTERIOESCLEROSIS, COMPOSICIoN FARMACÉUTICA Y COMPUESTOS INTERMEDIARIOS |
-
2002
- 2002-12-06 JP JP2003550741A patent/JP2005515206A/ja not_active Withdrawn
- 2002-12-06 IL IL16232502A patent/IL162325A0/xx unknown
- 2002-12-06 NZ NZ533413A patent/NZ533413A/en unknown
- 2002-12-06 BR BR0214842-0A patent/BR0214842A/pt not_active Withdrawn
- 2002-12-06 US US10/313,058 patent/US6777440B2/en not_active Expired - Lifetime
- 2002-12-06 MX MXPA04005623A patent/MXPA04005623A/es unknown
- 2002-12-06 RU RU2004119963/04A patent/RU2284315C2/ru not_active IP Right Cessation
- 2002-12-06 WO PCT/US2002/039092 patent/WO2003049690A2/en not_active Application Discontinuation
- 2002-12-06 HU HU0402675A patent/HUP0402675A2/hu unknown
- 2002-12-06 CA CA002469592A patent/CA2469592C/en not_active Expired - Fee Related
- 2002-12-06 TW TW091135471A patent/TWI252757B/zh not_active IP Right Cessation
- 2002-12-06 PL PL02370664A patent/PL370664A1/xx not_active Application Discontinuation
- 2002-12-06 EP EP02804741A patent/EP1467695A2/en not_active Withdrawn
- 2002-12-06 AU AU2002366604A patent/AU2002366604A1/en not_active Abandoned
- 2002-12-06 KR KR10-2004-7009018A patent/KR20040065251A/ko not_active Application Discontinuation
- 2002-12-06 CN CNA028279700A patent/CN1617849A/zh active Pending
- 2002-12-10 AR ARP020104777A patent/AR037770A1/es not_active Application Discontinuation
- 2002-12-11 UY UY27577A patent/UY27577A1/es not_active Application Discontinuation
- 2002-12-12 PE PE2002001198A patent/PE20030763A1/es not_active Application Discontinuation
-
2004
- 2004-06-09 CO CO04054295A patent/CO5590909A2/es not_active Application Discontinuation
- 2004-06-10 IS IS7305A patent/IS7305A/is unknown
- 2004-06-10 ZA ZA200404628A patent/ZA200404628B/en unknown
- 2004-06-11 HR HR20040534A patent/HRP20040534A2/hr not_active Application Discontinuation
- 2004-07-09 NO NO20042916A patent/NO20042916L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20042916L (no) | 2004-09-10 |
CA2469592A1 (en) | 2003-06-19 |
ZA200404628B (en) | 2005-09-01 |
CO5590909A2 (es) | 2005-12-30 |
IL162325A0 (en) | 2005-11-20 |
US20030176495A1 (en) | 2003-09-18 |
WO2003049690A3 (en) | 2004-01-22 |
EP1467695A2 (en) | 2004-10-20 |
MXPA04005623A (es) | 2004-12-06 |
CN1617849A (zh) | 2005-05-18 |
AU2002366604A1 (en) | 2003-06-23 |
CA2469592C (en) | 2005-08-23 |
BR0214842A (pt) | 2005-01-11 |
UY27577A1 (es) | 2003-07-31 |
RU2004119963A (ru) | 2006-01-10 |
NZ533413A (en) | 2006-09-29 |
PL370664A1 (en) | 2005-05-30 |
US6777440B2 (en) | 2004-08-17 |
KR20040065251A (ko) | 2004-07-21 |
TW200301105A (en) | 2003-07-01 |
PE20030763A1 (es) | 2003-09-13 |
WO2003049690A2 (en) | 2003-06-19 |
TWI252757B (en) | 2006-04-11 |
JP2005515206A (ja) | 2005-05-26 |
IS7305A (is) | 2004-06-10 |
HUP0402675A2 (hu) | 2005-03-29 |
AR037770A1 (es) | 2004-12-01 |
RU2284315C2 (ru) | 2006-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2469592C (en) | Hiv integrase inhibitors | |
US7109186B2 (en) | HIV integrase inhibitors | |
JP4528918B2 (ja) | カルボキサミド誘導体 | |
US20170326104A1 (en) | Ire-1alpha inhibitors | |
JP2011523956A (ja) | 癌の治療のために用いることができる化合物 | |
US20070299114A1 (en) | Biaryl Derivatives | |
AU2001269895B2 (en) | Hiv integrase inhibitors | |
CN102123763A (zh) | 富马酸氢甲酯的前体药物、其药物组合物、及其使用方法 | |
CA2838703C (en) | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | |
AU2001269895A1 (en) | HIV integrase inhibitors | |
CA2702536A1 (en) | Novel histone deacetylase inhibitors | |
JP2007501280A (ja) | 新規医薬組成物を用いた免疫調節 | |
JPH0322869B2 (is) | ||
SK4132003A3 (en) | Propionic acid derivatives, the process for their preparation, pharmaceutical composition comprising them, use thereof and intermediates for producing them | |
US6890942B2 (en) | Acyl sulfonamides as inhibitors of HIV integrase | |
JPH07138214A (ja) | 置換アミド酸誘導体 | |
JPH10251224A (ja) | 新規なチオカルバミン酸誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20051115 Year of fee payment: 4 |
|
OBST | Application withdrawn |